Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis

Study Title

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to ClinicFemale, Maley Definite Multiple Sclerosis of Subjects Presenting With ClinicFemale, Maley Isolated Syndrome

Teva Identifier

GA 9010

ClinicalTrials.gov Identifier

NCT00666224

Study Status

Completed

Trial Condition(s)

Multiple Sclerosis

Interventions

Drug: Glatiramer Acetate (DB)|Drug: Placebo | Drug: Glatiramer Acetate (OL)

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 45 Years

Trial Duration

01/01/2004 - 06/01/2010

Phase

Phase 3

Study Type

Interventional